10% discount rate (for additional-testing in men)
20 year time horizon (for additional-testing in men)
CE threshold $150 / DALY averted (for additional testing in men)
CE threshold $300 / DALY averted (for additional testing in men)
Additional-testing (beyond core-testing) only in women
Additional-testing (beyond core-testing) only in men
Percent of HIV diagnosed people with VL < 1000
73% - 83%**
Percent of HIV diagnosed people with VL < 1000
46% - 66%**
Probability of HIV test when have HIV symptoms
90% - 97%**
Probability of HIV test when have HIV symptoms
30% - 89%**
HIV incidence 0.79 - 3.38 / 100 pyrs**
HIV incidence 0.07 - 0.51 / 100 pyrs**
Undiagnosed HIV prevalence 1.93% - 6.95%**
Undiagnosed HIV prevalence 0.35% - 1.22%**
Cost of HIV clinic visits and clinical care x 5
Overall (base case)

* Lower/ ** upper tertile of the distribution across setting scenarios in 2017
No bar in red indicates that for over 20% of setting scenario / unit test cost combinations there is no cost of testing per diagnosis at which testing is cost-effective